Glycoprotein IIB/IIIA Receptor Inhibitors

Glycoprotein IIb/IIIa receptor inhibitors block GP IIb/IIIa from binding to fibrinogen, which inhibits platelet aggregation.  Abciximab is a monoclonal antibody that binds GP IIb/IIIa.  These drugs are used primarily for prevention of ischemic complications in percutaneous coronary intervention.  Bleeding is an adverse effect.

Class Drugs

• Abciximab

• Eptifibatide

• Tirofiban

Class Mechanism of Action

Blocks GP IIb/IIIa receptors

• Reduces platelet aggregation by blocking binding of fibrinogen and GP IIb/IIIa receptors

GP IIb/IIIa receptor inhibitor diagram

Class Applications

Prevention of cardiac ischemic complications in percutaneous coronary intervention

Class Adverse Effects

Bleeding, can be life threatening

Drug Table

Drug Name	Application	Comments	Image
Abciximab		Monoclonal Antibody	"Abs -Six Pack"
Eptifibatide			"Epstein" "Fib" "Tide"
Tirofiban			"Tire" "Fib"